Background: ccRCC, the most prevalent pathological subtype of renal cell carcinoma, has demonstrated a proclivity for drug resistance when treated with TKIs as a monotherapy. Notably, the integration of PD-1 blockade with TKIs has significantly enhanced patient survival, thereby emerging as a frontl...
ORGANISM(S): Homo sapiens